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Abstract
Background: Obesity is a multifactorial disease that arises from complex interactions between genetic predisposition and
environmental factors. Leptin is central to the regulation of energy metabolism and control of body weight in mammals.
Methodology/Principal Findings: To better recapitulate the complexity of human obesity syndrome, we applied N-ethyl-N-
nitrosourea (ENU) mutagenesis in combination with a set of metabolic assays in screening mice for obesity. Mapping revealed
linkage to the chromosome 6 within a region containing mouse Leptin gene. Sequencing on the candidate genes identified
a novel T-to-A mutation in the third exon of Leptin gene, which translates to a V145E amino acid exchange in the leptin
propeptide. Homozygous Leptin
145E/145E mutant mice exhibited morbid obesity, accompanied by adipose hypertrophy,
energy imbalance, and liver steatosis. This was further associated with severe insulin resistance, hyperinsulinemia,
dyslipidemia, and hyperleptinemia, characteristics of human obesity syndrome. Hypothalamic leptin actions in inhibition of
orexigenic peptides NPY and AgRP and induction of SOCS1 and SOCS3 were attenuated in Leptin
145E/145E mice.
Administration of exogenous wild-type leptin attenuated hyperphagia and body weight increase in Leptin
145E/145E mice.
However, mutant V145E leptin coimmunoprecipitated with leptin receptor, suggesting that the V145E mutation does not
affect the binding of leptin to its receptor. Molecular modeling predicted that the mutated residue would form hydrogen
bond with the adjacent residues, potentially affecting the structure and formation of an active complex with leptin receptor
within that region.
Conclusions/Significance: Thus, our evolutionary, structural, and in vivo metabolic information suggests the residue 145 as
of special function significance. The mouse model harboring leptin V145E mutation will provide new information on the
current understanding of leptin biology and novel mouse model for the study of human obesity syndrome.
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Introduction
Leptin, a 16-kDa protein produced mainly in adipose tissue and
secreted into the bloodstream, plays an important role in
regulating body weight, metabolism and reproductive function
[1]. Circulating leptin levels are highly correlated with white
adipose tissue mass. The lack of leptin action causes a disruption in
energy balance with hyperphagia and decreased energy expendi-
ture, leading to morbid obesity and development of type 2
diabetes. Leptin administration decreases food intake and body
weight while preserving metabolic energy utilization. Although
obese animals and humans frequently have elevated circulating
leptin levels, their leptin fails to mediate weight loss, implicating
resistance to the action of leptin in obese states.
Mouse and human leptin cDNA encodes a 167 amino acid
residue protein with a 21 amino acid residue signal sequence that
is cleaved to yield the 146 amino acid residue mature protein.
Mouse leptin shares approximately 96% and 84% sequence
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four-helix bundle (helices A–D) cytokine structure with an up-up-
down-down topology [2], resembling G-CSF and the cytokines of
the IL-6 and gp130 family [3].
Hypothalamus is an important site for leptin action, which is
mediated by its specific receptor, leptin receptor. Leptin receptor
shows highest sequence similarity with the receptors of the IL-6
and gp130 family and the G-CSF receptor [4,5]. Binding of leptin
to leptin receptor in the hypothalamus results in the recruitment
and activation of JAK2. Activated JAK2 phosphorylates cytoplas-
mic domain of leptin receptor, leading to activation and nuclear
translocation of STAT3. These in turn modulate transcriptional
activity of numerous neuropeptides involved in feeding and energy
expenditure, including proopiomelanocortin (POMC), neuropep-
tide Y (NPY) and agouti-related peptide (AgRP).
Several animal models of monogenic obesity involve mutations
in leptin (Leptin
ob/ob mice) or its receptors (Lepr
db/db mice and fa/fa
rats). The obese phenotype of Leptin
ob/ob mice is caused by
mutations in either the coding region (ob
(1J)) [6] or the 59 non-
coding region (ob
(2J)) [7] of mouse Leptin gene. Serum leptin level is
undetectable in both mutant mice. Mutations in human LEPTIN
gene have also been reported [8]. Homozygous frameshift
(DG133) [9] and missense (R105W) [10] mutations of LEPTIN
gene have been identified in patients with morbid obesity. These
mutations result in an inability to produce/secrete the leptin
protein, with undetectable levels in the serum of affected
individuals. Heterozygosity for leptin mutations is associated with
an increase in body weight [11]. In contrast, other leptin missense
mutations identified in humans do not appear to influence body
weight [12,13].
To better recapitulate the complexity of human obesity
syndrome, we applied a systemic, genome-wide, and phenotype-
driven approach in screening of N-ethyl-N-nitrosourea (ENU)-
treated mice for obesity. We report here the identification of a novel
T-to-A mutation in exon 3 of mouse Leptin gene, causing a Val to
Glu amino acid exchange in the codon 145 of leptin propeptide.
Homozygous mutant mice became obese and hyperphagic at
weaning. These obese mice continued to gain weight and develop
severe hyperinsulinemia and insulin resistance. In contrast to the
absence of immunoreactive leptin protein in the circulation of
Leptin
ob/ob mice, homozygous Leptin
145E/145E mice exhibited mark-
edly increased leptin levels in circulation. The mouse model
harboring leptin V145E mutation will serve as an excellent model
for human obesity which results from leptin dysfunction.
Results
ENU-induced obese mice harbor a mutation in leptin
During an ENU mutagenesis screen, we found several obese mice
fromthesameG1founderinheritedinarecessivepattern(Figure1A).
Mapping and haplotype analysis established the mutation on
chromosome 6 within a 2.6 Mb region between rs33791073 and
rs13478688 (Figure 1B). Sequence analysis on the candidate genes
within this 2.6 Mb region revealed a T-to-A transversion in exon 3 of
Leptin gene in homozygous ENU-induced obese mice (Figure 1C).
This transversion translates into a Val to Glu amino acid exchange in
the codon 145 of propeptide, corresponding to residue 124 of the
matureprotein.Val-145anditsnearbyaminoacids,locatedintheN-
terminal domain of helix D of leptin protein, are highly conserved
between different species (Figure 1D).
Leptin
145E/145E mice are obese and hyperphagic
Regular chow fed homozygous Leptin
145E/145E mice were
extremely obese and infertile. At about 6 weeks of age, body
weight of Leptin
145E/145E mice was doubled as those of heterozy-
gous Leptin
145E/+ and wild-type Leptin
+/+ littermates (Figure 2A).
The growth curves of both male and female Leptin
145E/145E mice
were steeper than those of Leptin
+/+ mice fed regular chow
(Figure 2B). Despite the marked increase of body weights in
Leptin
145E/145E mice, body lengths of Leptin
145E/145E mice were
longer than Leptin
+/+ mice by about 7% (Figure 2C). No difference
was detectable on pancreas and spleen weights between genotypes
(Figure 2D). Kidney and heart weights of Leptin
145E/145E mice were
significantly increased, compared with those of Leptin
+/+ mice.
Liver of Leptin
145E/145E mice were tripled in weight and pale in
appearance. Histological analysis identified vacuolization and lipid
accumulation in the liver (Figure 2E), suggestive of steatosis in
Leptin
145E/145E livers.
To further analyze the individual fat weight, we dissected
gonadal fat to represent intra-abdominal white adipose tissue
(WAT), inguinal fat to represent subcutaneous WAT, and
interscapular brown adipose tissue (BAT). The gonadal WAT
mass in Leptin
145E/145E mice were about 8-fold that of Leptin
+/+
mice (Figure 3A). An 18-fold increase in weight was observed in
subcutaneous inguinal fat pads of Leptin
145E/145E mice. The
interscapular BAT weight of Leptin
145E/145E mice was about 2-
fold that of wild-type mice.
Microscopically, adipocytes in BAT exhibited markedly en-
larged lipid droplets with unilocular lipid deposition in chow-fed
Leptin
145E/145E mice (Figure 3B). Adipocytes in gonadal WAT of
Leptin
145E/145E mice were larger than Leptin
+/+ cells (mean
area 2136 mm
2 in Leptin
145E/145E versus 897 mm
2 in Leptin
+/+)
(Figure 3C). Similar difference was detected in inguinal WAT of
Leptin
145E/145E mice (mean area 2040 mm
2 in Leptin
145E/145E versus
837 mm
2 in Leptin
+/+). Thus, the V145E mutation of leptin brought
a shift of adipocyte size-distribution toward larger in WAT
(Figure 3D). Based on the calculation by DiGirolamo et al. [14],
we estimate that the number of adipocytes was doubled in gonadal
WAT of Leptin
145E/145E mice (5.1610
7 in Leptin
145E/145E versus
2.1610
7 in Leptin
+/+). The number of adipocytes in inguinal WAT
of Leptin
145E/145E mice (6.2610
7) was markedly more than that of
Leptin
+/+ mice (1.5610
7). In addition to adipocyte hypertrophy and
hyperplasia, a number of crown-like structures, which reflect the
focal convergence of macrophages surrounding necrotic adipo-
cytes, were prevalent in gonadal fat depots of Leptin
145E/145E mice.
A marked expansion in cell volume together with the striking
increase in cell number thus account for massive increase in fat
mass of Leptin
145E/145E mice.
Leptin
145E/145E mice had increased daily food intake and caloric
absorption compared with those of Leptin
+/+ littermates (Figure 4A).
Because Leptin
145E/145E mice weighed more than Leptin
+/+ mice, the
feeding efficiency was significantly increased in Leptin
145E/145E mice.
Fecal and urine outputs were slightly increased in Leptin
145E/145E
mice (Figure 4B), despite similar water intake between genotypes. In
addition, body temperature was significantly decreased in both light
and dark cycles (Figure 4C). Thus, Leptin
145E/145E mice exhibited
energy imbalance, with increased energy intake and reduced energy
dissipation.
Leptin
145E/145E mice exhibit impaired insulin sensitivity
To investigate the effect of leptin V145E mutation on glucose
homeostasis, we examined the levels of glucose and insulin. The
serum glucose and insulin levels after fasting were both
significantly higher in Leptin
145E/145E mice than those in Leptin
+/+
mice on a regular chow (Figure 5A). To examine the whole-body
glucose utilization in Leptin
145E/145E mice, we performed the oral
glucose tolerance test (OGTT). Leptin
145E/145E mice cleared
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+/+ mice did, indicating glucose
intolerance in Leptin
145E/145E mice (Figure 5B). This decreased
glucose tolerance was accompanied by significantly increased
plasma insulin levels during the OGTT of Leptin
145E/145E mice.
Thus, the IR index calculated from the OGTT was markedly
increased in Leptin
145E/145E mice (Figure 5C). Consistently, insulin
tolerance tests showed that glucose lowering effects of insulin were
severely impaired in Leptin
145E/145E mice (Figure 5D). We noticed
the initial increase of blood glucose by insulin injection in
Leptin
145E/145E mice. The similar observation was demonstrated
in other mouse models with severe insulin resistance [15]. Thus,
the initial increase of blood glucose by insulin injection in
Leptin
145E/145E mice appears to be the consequence of a stress
response to handling in the presence of complete insulin
unresponsiveness. These results demonstrated that the V145E
mutation of leptin impaired glucose tolerance and insulin
sensitivity.
Adipose tissues actively secrete signaling molecules, including
lipid and adipokines, into the circulation that communicate with
other organs to regulate insulin sensitivity [16]. Fasting serum
triglyceride and cholesterol levels were significantly higher in
Leptin
145E/145E mice than in Leptin
+/+ mice (Figure 5E). Although
circulating adiponectin levels were not altered, serum leptin levels
were dramatically increased in Leptin
145E/145E (Figure 5F). These
results imply that the V145E mutation causes the defect in leptin
function, leading to a compensatory induction in production of
more defective leptin proteins.
Leptin
145E/145E mice exhibit impaired leptin action in the
hypothalamus
An important component of leptin action is mediated by the
hypothalamus, where leptin promotes expression of anorectic
neuropeptide proopiomelanocortin (POMC) and inhibits produc-
tion of orexigenic neuropeptides neuropeptide Y (NPY) and
agouti-related peptide (AgRP) [1]. To determine the effect of
V145E mutation on leptin action in the hypothalamus, we
examined neuropeptide mRNA expression in hypothalami from
mice 8-hour post-feeding, at which circulating leptin levels are
raised. While POMC mRNA tended to be lower in Leptin
145E/145E
mice than in Leptin
+/+ and Leptin
145E/+ mice, both NPY and AgRP
mRNA levels were significantly increased in Leptin
145E/145E mice
(Figure 6A). We also examined mRNA expression for the
suppressor of cytokine signaling, SOCS1 and SOCS3, which are
known to be induced by leptin [17]. Both SOCS1 and SOCS3
mRNA levels were significantly decreased in Leptin
145E/145E mice
(Figure 6A). However, V145E mutation did not affect the
expression of leptin receptor (LEPR). Thus, the obese and
hyperphagic phenotypes of Leptin
145E/145E mice may result in part
from attenuated leptin action in the hypothalamus.
Figure 1. Identification of the leptin mutation in the ENU-induced obese mice. (A) Mating and screening strategy for isolation and
maintenance of the ENU-induced obese mice. The detail of breeding strategy is summarized in the Materials and Methods. (B) Mapping and
haplotype analysis for the mutation in the ENU-induced obese mice. Black boxes represent homozygotes for C57BL/6J/C57BL/6J and white boxes
represent either C57BL/6J/BALB/c heterozygotes or BALB/c/BALB/c homozygotes. The number of progeny inheriting each haplotype is listed in the
bottom. Haplotype analysis indicates that the mutation falls within a 2.6 Mb region (arrow) between rs33791073 and rs13478688 on chromosome 6.
(C) Sequencing traces a T-to-A transversion (asterisk) in exon 3 of Leptin gene, causing a V145E substitution. (D) Val-145 and its nearby amino acids,
located in the N-terminal of helix D (box) of leptin protein, are conserved throughout species.
doi:10.1371/journal.pone.0015333.g001
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145E/145E
mice, we examined the physiological response to low-dose leptin
treatment in Leptin
145E/145E mice. Exogenous wild-type leptin
administration resulted in a more than 10% decrease in body
weight (Figure 6B), and decreased feeding by approximately 60%
(Figure 6C). Thus Leptin
145E/145E mice are sensitive to the
exogenous administration of wild-type leptin, suggesting the
mutant V145E leptin is not functional. To further examine the
interaction between mutant V145E leptin and leptin receptor,
coimmunoprecipitation analysis was performed from brain using a
leptin receptor antibody. Indeed, mutant V145E leptin coimmu-
noprecipitated with leptin receptor (Figure 6D), suggesting that the
V145E mutation does not affect the binding of leptin to its
receptor.
Comparison of metabolic profiles between Leptin
145E/145E
and Leptin
ob/ob mice
To compare the metabolic outcome of the V145E mutation in
leptin with that of the nonsense mutation at codon 105 of leptin
identified in Leptin
ob/ob (ob
(1J)) mice [6], we examined their metabolic
parameters in accompany with their respective wild-type littermate
controls. We found that Leptin
145E/145E mice have relatively less
weight than age-matched Leptin
ob/ob mice, although the weights of
their respective wild-type littermate controls were similar (Table 1).
Both gonadal and inguinal fat weights relative to their body weights
were similar between Leptin
145E/145E and Leptin
ob/ob mice. The ratios
of liver to body weights were similar between Leptin
145E/145E and
Leptin
ob/ob mice. Although Leptin
145E/145E mice had less body weight,
Leptin
145E/145E mice doubled their IR indices compared with age-
matched Leptin
ob/ob mice. These results demonstrate that the V145E
mutation in leptin results in less adiposity, but more severe
insulin resistance, than the truncated premature stop at codon
105 of leptin.
Effect of V145E mutation on tertiary structure of leptin
To examine the effect of V145E mutation on the structure of
leptin, we performed the molecular dynamics simulations on wild-
type and mutant V145E leptin. Because leptin has high sequence
identity among diverse species including human and mouse, the
mouse leptin structure was constructed based on the only available
X-ray crystal structure of human leptin [2]. Val-145 is located in
the N-terminal region of the helix D (Figure 7A). The V145E
substitution does not change the overall secondary structure (data
not shown) and tertiary structure (Figure 7A). However, a closer
inspection on the region of residue 145 indicated that the
substitution of valine to glutamic acid with a relatively bulky and
positively charged side chain enhances the interstrand interaction
through hydrogen bonds formed with the adjacent residues Arg-
149, Glu-136 and Arg-56 (Figure 7B). These suggest that the
V145E mutation could potentially affect the tertiary structure and
formation of an active complex with leptin receptor of this area
formed by the residues on helix D, helix E and AB loop.
Discussion
Using the random ENU-mutagenesis, we created a novel mouse
model inherited in a recessive pattern for obesity and insulin
resistance due to a missense V145E mutation in the Leptin gene. The
V145E mutation of leptin leads to a phenotype of extreme obesity,
characterized by adipocyte hypertrophy and hyperplasia, positive
energy imbalance, and liver steatosis. This was further associated with
severe insulin resistance, hyperinsulinemia, dyslipidemia, and
hyperleptinemia, characteristics of human obesity syndrome.
Figure 2. Morbid obesity in Leptin
145E/145E mice. (A) Increased body weight in Leptin
145E/145E mice compared with their Leptin
145E/+ and Leptin
+/+
littermates. (B) Growth curves and photograph of male Leptin
145E/145E mice (n=5) and their Leptin
+/+ littermates (n=9). (C) Body lengths of 4-month-old
male Leptin
145E/145E and Leptin
+/+ mice. (D) Organ weights from Leptin
145E/145E (n=11) and Leptin
+/+ mice (n=19). (E) Liver histology of Leptin
145E/145E
and Leptin
+/+ mice. Numbers of mice are inside bars. **P,0.01 and ***P,0.001 between two genotypes.
doi:10.1371/journal.pone.0015333.g002
A Novel Leptin Mutation in Mice
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independent strains of Leptin
ob/ob mice. In the ob
(1J) allele on the
C57BL/6J background, a nonsense mutation at codon 105 (residue
84 of the mature protein) results in the synthesis of a truncated
protein that is degraded in the adipocyte [6]. In the ob
(2J) allele on
the SM/Ckc-+
DAC background, an approximately 5-kb transposon
is inserted into the first intron of Leptin gene [7]. This mutation
results in the synthesis of hybrid RNAs and fails to synthesize
mature leptin RNA. To our knowledge, the Leptin
145E/145E
mouse model represents the first leptin missense mutation in
rodents. The addition of this novel point mutation and its associated
phenotype, due to functional alterations in the protein rather than
complete lack thereof will prove valuable for understanding the in
vivofunction ofleptin.In addition,thefailure ofelevated leptinlevels
to mediate weight loss and inhibition of orexigenic neuropeptides
suggests the loss of leptin action, and confirms the functional
significance of this residue in leptin.
To date, only few LEPTIN mutations have been reported in the
obese patients. A deletion of a guanidine at codon 133 (DG133;
corresponding to residue 112 of the mature protein), resulted in
the premature stop at position 145, was first reported in two
siblings of Pakistani origin [9]. The truncated mutant leptin is
misfolded and not secreted. Obese subjects with this mutation
express very low or undetectable leptin in the serum. A missense
mutation in codon 105 (R105W; residue 84 of the mature protein),
that is the same codon mutated in Leptin
ob/ob (ob
(1J)) mice, was
uncovered in a Turkish family with morbid obesity [10]. The
leptin synthesized in these patients is not secreted in serum.
Another missense mutation (N103K) was reported in two Egyptian
siblings with severe early onset obesity [18]. However, several
missense mutations, including I45V, V110M and E126Q, that do
not appear to influence body weight have also been identified
[12,13,19].
Although three-dimensional structure of leptin was solved [2],
the structure of leptin receptor has not yet been determined. The
mechanism of leptin-induced leptin receptor activation remains
unclear. Our current understanding of molecular interaction of
leptin binding to leptin receptor is largely based on homology
modeling with other cytokine complex crystal structures [20].
Leptin has been suggested to have three different binding sites I,
II, III that interact with leptin receptor [21,22]. Binding site I,
which is thought to be involved in the binding of cytokine receptor
homology 1 (CRH1) or CRH2 domain of leptin receptor, appears
at the C-terminal region of helix D. Binding site II, which binds to
the CRH2 domain of leptin receptor, is composed of residues at
the surface of helix A and C. Binding site III, which binds to the
Figure 3. Increased fat deposition in Leptin
145E/145E mice. (A) Fat mass of gonadal (Gon) and inguinal (Ing) WAT and interscapular BAT of
Leptin
145E/145E (n=7,11) and Leptin
+/+ mice (n=19). **P,0.01 and ***P,0.001 against Leptin
+/+. Morphology of (B) BAT and (C) gonadal and inguinal
WAT from 4-month-old male mice. (D) Distribution of cell size in gonadal (n=3 each) and inguinal (n=3 each) WAT of Leptin
145E/145E and Leptin
+/+
mice.
doi:10.1371/journal.pone.0015333.g003
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by the residues at interface between the N terminus of helix D and
the AB loop.
Val-145 resides in the N-terminal region of the helix D
(Figure 7A), containing domains important for binding site III of
leptin. Val-145 and its surrounding residues (YSTEVVALSRLQ,
amino acids 140,151, black boxed in Figure 1D) are strictly
conserved in different species. The substitution of valine to
glutamic acid with a sterically larger and positively charged side
chain therefore could interfere with relatively hydrophobic
environment of the binding site III [23,24]. This could potentially
alter the tertiary structure and formation of an active complex with
leptin receptor in this interaction site. Alternatively, the mutated
residue Val-145 might be critical for receptor activation by
inducing allosteric changes in the receptor upon binding. Finally,
we cannot exclude that Val-145 is involved in binding of a yet
unidentified domain on leptin receptor.
Although binding site II is thought to be the main high affinity
binding site of leptin for leptin receptor [22,25,26], binding site III
of leptin has been suggested to be responsible for formation of an
active multimeric complex and subsequent activation of leptin
receptor [5,27]. Binding site III consists of rather large
hydrophobic fragment in the gp130 cytokines [23,24]. Extensive
mutagenesis of mouse and human leptins identified several critical
amino acid residues in the N-terminal part of helix D, as main
contributors to binding site III. For example, leptin with mutations
on Ser-141 and Thr-142 totally lost its ability to activate leptin
receptor but showed normal binding to leptin receptor [5].
Figure 4. Energy imbalance in Leptin
145E/145E mice. (A) Daily food intake, energy intake, and feeding efficiency; (B) fecal output, urine output
and water intake; (C) rectal temperature in Leptin
145E/145E and Leptin
+/+ mice. Numbers of mice are inside bars. *P,0.05, **P,0.01, and ***P,0.001
against Leptin
+/+.
doi:10.1371/journal.pone.0015333.g004
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mutants exhibit antagonistic activity and block activation of leptin
receptor in a dose dependent manner. Another leptin mutation
Y140A did not change the binding, but decreased drastically the
agonistic activity [27]. Thus mutation located in or close to the
binding site III is likely to weaken the interaction with IGD, which
would further impair the receptor activation.
Two other leptin mutations, S148D and R149Q, within the N-
terminal part of helix D have also been described. Although these
two mutations do not affect the binding to the mouse leptin
receptor, they cause reduced biological activity [28]. Of particular,
R149Q is unable to trigger intracellular signaling and behaves as a
competitive inhibitor [29]. Although Arg-149 has not been
predicted part of any of the three binding sites, this residue forms
hydrogen bonds with the backbone of Pro-64 (in AB loop) and
Val-134 (in helix E). Thus, the R149Q mutation has been thought
to disturb the proper orientation of the AB loop and helix D, and
possibly indirectly affect binding site III [2]. Importantly, the
outwardly projecting, positively charged side chain of glutamic
acid from mutated reside 145 is predicted to form hydrogen bond
with the adjacent residues Arg-149, Glu-136 and Arg-56
(Figure 7B). These suggest that the V145E mutation could
potentially affect the role of residue Arg-149 in maintenance of
proper environment of binding site III and correct interaction with
the receptor. Consistent with the results of leptin mutations on
Y140, S141, T142, S148, and R149, the V145E mutation does
not appear to affect the binding of leptin to its receptor, despite
largely attenuated agonistic activity of leptin.
The adiposity of Leptin
145E/145E mice follows the trend of
Leptin
ob/ob mice, although the severity is reduced. The difference
was also evident when comparing both genotypes in female mice
(data not shown). Despite the difference in adiposity, the
percentage of individual fat mass, as well as liver weight, was
similar between Leptin
145E/145E and Leptin
ob/ob mice. In contrast,
Leptin
145E/145E mice exhibited more impairment in glucose
metabolism, reflected in the two-fold increase in IR indices.
Because both ENU-induced Leptin
145E/145E and spontaneously-
mutated Leptin
ob/ob mice were maintained in C57BL/6, the
differences cannot be attributed to their genetic background.
Although the phenotypic characterizations of Leptin
145E/145E and
Leptin
ob/ob mice were carried out in different sets of experiments,
their respective wild-type littermate controls were used in each set
of experiment. Based on the similar values between two respective
wild-type littermate controls, it is reasonable to compare the
magnitude of increases in body fat and insulin resistance.
Currently, we cannot exclude the possibility that the obese
phenotype in our mutants is accentuated by the concomitant
modification of the nearby genes. However, the markedly
increased immunoreactive leptin level in circulation suggests a
compensatory mechanism to increase the demand for leptin to
regulate the energy imbalance. Furthermore, administration of
exogenous wild-type leptin attenuated hyperphagia and body
weight increase in Leptin
145E/145E mice. Therefore, it is likely that
the phenotype is entirely attributable to the nonfunctional V145E
leptin protein.
The normal level of adiponectin in Leptin
145E/145E mice is
contradicted to the general concept of reduced circulating
adiponectin in human obesity syndrome. However, the inconsis-
tency between low circulating adiponectin and obesity/diabetes
was also reported in several obese mouse models. For example, a
tendency of increase or no difference in plasma adiponectin levels
was reported in obese mice with a dominant mutation in Nmf15
locus [30], Leptin
ob/ob mice [31], and a polygenic obese mouse
strain NONcNZO5 [32]. This can partly be explained by the
Figure 5. Severe hyperinsulinemia and insulin resistance in Leptin
145E/145E mice. (A) Serum glucose and insulin levels during 5-hr fasting of
Leptin
145E/145E and Leptin
+/+ mice. (B) Serum glucose and insulin levels during glucose tolerance tests in 3-month-old male littermates (n=5,9).
Impaired insulin sensitivity revealed by (C) IR index and (D) insulin tolerance tests of 3-month-old female Leptin
145E/145E mice (n=8) compared to
Leptin
+/+ mice (n=10). (E) Fasting serum triglyceride (TG, left panel), cholesterol (Chol, middle panel), and free fatty acid (FFA, right panel). (F) Serum
levels of adiponectin (left panel) and leptin (right panel) of Leptin
145E/145E and Leptin
+/+ mice. Numbers of mice are inside bars. *P,0.05, **P,0.01, and
***P,0.001 against Leptin
+/+.
doi:10.1371/journal.pone.0015333.g005
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temporarily compensate for decreased adiponectin production
per unit of fat.
In summary, we successfully used an ENU-based mutagenesis
approach in combination with a set of metabolic assays to identify
and characterize a novel mouse model with leptin V145E
mutation. Two Leptin
ob/ob mouse lines with spontaneously mutated
leptin cannot completely model human obesity syndrome because
the leptin protein is completely lacking in the serum of those mice.
Although residue Val-145 has not been reported to be mutated in
humans, our evolutionary, structural, and in vivo metabolic
information implicates this residue as of special functional
significance. Among LEPTIN mutations reported thus far in
human obesity, DG133 and R105W mutations result in an
inability to produce/secrete the leptin protein, with undetectable
levels in the serum of affected individuals [9,10]. To our
knowledge, the N103K mutation in patients with severe obesity
is the only known human mutation that has been demonstrated to
disrupt receptor binding [33]. However, our results suggest that
the V145E mutation does not affect the binding of leptin to its
Figure 6. Hypothalamus gene expression and leptin sensitivity in Leptin
145E/145E mice. (A) Expression of genes for neuropeptides, including
POMC, NPY and AgRP; and SOCS1, SOCS3, and LEPR in the hypothalamus of Leptin
145E/145E mice (n=5) compared with their Leptin
145E/+ (n=12) and
Leptin
+/+ (n=5) littermates. mRNA amount is expressed relative to the average expression in the hypothalamus of Leptin
+/+ mice. Leptin sensitivity in
Leptin
145E/145E mice revealed by (B) body weight and (C) daily food intake. Leptin
145E/145E mice (n=3) and control littermates (including both Leptin
145E/+
and Leptin
+/+; n=3) were injected intraperitoneally twice daily with PBS or leptin (1 mg/kg) for three days. (B) Body weight and (C) average daily food
intake during injection period. Day 0 represents the average weight before leptin injection. *P,0.05 and **P,0.01 between two genotypes/groups.
#P,0.05 against PBS-treated Leptin
145E/145E mice. (D) Interaction between leptin and leptin receptor in the mid brain was examined by
coimmunoprecipitation. Brain lysates from Leptin
+/+, Leptin
145E/+ and Leptin
145E/145E mice were immunoprecipitated with anti-leptin receptor antibody,
and immunoblotted with anti-leptin or anti-leptin receptor antibodies. Each band represents the tissue extract mixed from three mice.
doi:10.1371/journal.pone.0015333.g006
Table 1. Comparison of metabolic profiles between Leptin
145E/145E and Leptin
ob/ob mice.
Set of experiment ENU ob/ob
Genotype Leptin
145E/145E Leptin
+/+ Leptin
ob/ob Leptin
+/+
B.W. (12w) 48.8062.79 26.7860.39 54.1960.61 25.9560.51
B.W. (13w) 51.0062.64 27.3360.45 56.3060.68 26.1860.46
Organ weight (% of B.W.)
Gonadal 3.5760.32 0.4160.03 4.1360.16 0.3860.02
Inguinal 4.0760.29 0.2760.02 3.4060.10 0.2160.02
Liver 3.3660.31 1.0860.04 3.4260.19 1.3360.04
IR index 70.3567.24 4.2660.58 39.4562.47 5.1760.35
Organ weights represent % body weights. B.W., body weight.
doi:10.1371/journal.pone.0015333.t001
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epidemiology or in vitro study using human ES cell systems, are
necessary to elaborate correlations between leptin V145E
mutation and the severity of obese phenotype in humans. In
addition, studies are required to gain further insights on how leptin
mutations, not only this V145E mutation, but also other mutations
identified in humans, affect the binding to and subsequent
activation of leptin receptor. Finally, the V145E substitution in
the N-terminus of helix D supplements the known mutations in
human and mouse leptin and thereby offers novel mouse model
for the study of human obesity syndrome.
Materials and Methods
ENU mutagenesis and identification of the mutant
C57BL/6J male mice were treated with ENU (100 mg/kg/week)
for 3 weeks [34] at the age of 8 weeks to generate G0 mice. G0 mice
were then mated with wild-type female C57BL/6J mice to generate
G1 mutagenized founder mice (illustrated in Figure 1A). G1 male
mice were mated with wild-type female C57BL/6J mice to generate
G2 mice. G2 female mice were backcrossed with G1 male mice to
generate G3 mutagenized mice. Several obese mice were found
from the same G1 founder (No. 341). One of the obese mice was
examined for heredity by a three-generation breeding scheme.
Because the obese mice were unable to impregnate the female mice,
in vitro fertilization (IVF) was conducted to generate F1 mice which
were intercrossed to generate F2 mice. Leptin-deficient (Leptin
ob/ob)
mice on a C57BL/6J background were obtained from the Jackson
Laboratory.Micewerefedwitharegularchow(LabDiet5P76;PMI
Nutrition International, Richmond, IN). Animals were housed in
a specific-pathogen-free barrier facility, and handled following
procedures approved by the IACUC of Academia Sinica
(OMiVGHHC2005108), Taipei Veterans General Hospital (96–
160), and National Cheng Kung University (98006).
Mapping and sequencing for the mutation
Mapping of the mutation was performed using a standard outcross
strategy to BALB/c mice in combination with SNP markers specific
for the C57BL/6J and BALB/c strains. Seven obese and seven non-
obese F2 mice were selected for initial mapping in which 275 SNPs
were used. One region located between 17 and 76 Mb of
chromosome 6 was found to have complete linkage with obesity.
To further narrow the interval, primers and probes flanking the SNPs
in the linked region were designed in multiplex format using
SpectroDESIGNER software (Sequenom, San Diego, CA). SNP
genotyping was performed by high-throughput MALDI-TOF mass
spectrometry [35]. Gene mapping analysis was conducted by
constructing and comparing figures as shown in Figure 1B. All
coding DNA was sequenced using a BigDye dideoxy-terminator
system and analyzed on an ABI 3700 sequencer (Applied Biosystems,
Foster City, CA). The mutant leptin sequence reported here was
deposited in GenBank under accession number HQ166716.
Metabolic analysis
Daily food intake was examined using metabolic cages (Solo
Mouse Metabolic Cage, Tecniplast, Italy). Daily energy intake was
Figure 7. Comparison of tertiary structure of wild-type (V145) and mutant (E145) leptin. (A) Tertiary structure of human leptin (left panel)
from X-ray crystallography, and wild-type (V145, middle panel) and mutant (E145, right panel) mouse leptins by homology modeling. The four-helical
bundle (helices A–D) structure with an additional short helical segment E is shown. The N and C termini are indicated. (B) Residue 145 and its
adjacent site in wild-type and mutant leptins. The hydrogen bonds between residues are shown as yellow dotted lines. The presented structures
were taken from snapshots close to the end of 6 ns simulations.
doi:10.1371/journal.pone.0015333.g007
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gross energy for regular chow 4.07 kcal/gm. Feeding efficiency
was calculated by dividing the weight increase by their feed
consumption over one month of the study [36]. Daily fecal and
urine output and water consumption were determined. Rectal
temperature was recorded by thermometer (TH-8, Physitemp
Instruments, Clifton, NJ).
Morphological analysis
Paraffin sections (10 mm) of adipose tissues isolated from male
mice (n=3 each) at 16 weeks of age were stained with H&E.
Adipocyte size was measured in 500 cells per mouse in several
parts of the gonadal and inguinal fat pads using Nikon NIS
Elements AR 2.30 software. Mean adipocyte number was
determined by dividing the mean fat mass by the mean fat cell
size as described previously [14].
Oral glucose tolerance and intraperitoneal insulin
tolerance tests
Mice were fasted for 5 hr and orally gavaged with glucose (2 g/
kg body weight) or intraperitoneally injected with human regular
insulin (0.35 U/kg body weight, Humulin, Eli Lilly, Indianapolis,
IN). Blood samples were collected before and at indicated times
after injections. Serum glucose concentration was determined by a
glucose colorimetric test (Autokit Glucose, Wako Chemicals USA,
Richmond, VA). Insulin was measured using mouse insulin ELISA
(Ultrasensitive Mouse Insulin ELISA, Mercodia, Sweden). The IR
index was calculated as the product of the areas under glucose and
insulin curves in glucose tolerance tests as previously described
[37].
Lipid and adipokine assays
Serum total cholesterol (Cholesterol E, Wako, Osaka, Japan),
free fatty acid (NEFA C, Wako, Osaka, Japan) and triglyceride
(Stanbio Laboratory, San Antonio, TX) were measured following
each protocol. Serum levels of adiponectin and leptin were
determined by ELISA (R&D Systems, Minneapolis, MN).
Tissue collection and RNA analysis
Hypothalami were isolated from 8-hr post fed mice and stored
in RNAlater (Ambion, Austin, TX), and RNA was extracted using
the TRIzol Reagent (Invitrogen, Carlsbad, CA). mRNA were
analyzed with SYBR green-based realtime quantitative RT-PCR
(Applied Biosystems, Foster City, CA), with b-actin as reference
gene in each reaction.
In vivo leptin sensitivity
Mice of 1.5,3 months of age were intraperitoneally injected
twice daily with PBS for initial three days, and then with PBS or
murine wild-type leptin (1 mg/kg; PeproTech, Rocky Hill, NJ) for
the following consecutive three days. Mice were weighed daily and
daily food intake was determined during the injection period.
Coimmunoprecipitation and protein analysis
Mid brain from mice were isolated and homogenized in RIPA
buffer containing protease inhibitors. 500 mg of total protein from
each lysate was immunoprecipitated with 10 mg of anti-leptin
receptor antibody (ab5593; Abcam, Cambridge, MA) pre-coupled
with protein A magnetic beads (LSKM AGA 10; Millipore,
Bedford, MA). Immunoprecipitated proteins were separated by
15% SDS-PAGE and transferred to a PVDF membrane.
Membranes were incubated with anti-leptin antibody (1:4000,
ab3583; Abcam) or anti-leptin receptor antibody (1:2000, ab5593;
Abcam) and visualized using a chemiluminescence detection
system (Millipore).
Structure modeling
Molecular dynamics simulations on wild-type and mutant
mouse leptin was performed based on the X-ray structure of
human leptin (PDB entry code: 1ax8) where the AB loop was too
flexible to be determined. In our homology modeling to construct
the rat leptin, the AB loop was included. The following modeling
procedures were used: (1) amino acid residues were added,
deleted, or replaced with appropriate residues manually; (2) the
structure was energy minimized with Steepest Descent and
Conjugate Gradient algorithms. The obtained structure was used
for wild-type and for replacing V145 to generate V145E mutant.
Both structures were gradually heated to 300 K for 150 ps and
additional 6 ns was performed for data collection. The charmM
force field was adopted, and time step was set at 2 fs. All the
modeling was carried out using the Discovery Studio 2.1 and done
with implicit distance-dependent dielectrics solvent model. The
SHAKE algorithm was used to constrain all bonds that contain
hydrogen atoms; the particle-mesh-Ewald (PME) was introduced
for long range electrostatic interactions.
Data analysis
Values are reported as mean 6 s.e.m.. Statistical analysis was
conducted by multifactorial ANOVA with genotype, gender, and
age as factors. Student’s t-test was used for comparisons between
mutant and wild-type mice within each group, and differences
were considered to be statistically significant at P,0.05.
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